MedTrace Logo

Safety and Tolerability of Intravenous Administration of ICVB-1042

NCT05904236 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-04-08

No results posted yet for this study

Summary

Study to evaluate the safety and tolerability of intravenous ICVB-1042

Conditions

  • Patients With Advanced Solid Tumors

Interventions

DRUG

Treatment with ICVB-1042 administered intravenously

Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels

Sponsors & Collaborators

  • IconOVir Bio

    lead INDUSTRY

Principal Investigators

  • Julie Maltzman, MD · IconOVir Bio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-12-11
Completion
2024-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05904236 on ClinicalTrials.gov